In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron and Roche Bury the Hatchet--for Now

Executive Summary

After years of jousting over Chiron's HCV patents, Chiron and Roche have finally come to an agreement, or at least a partial agreement--with implications for anyone working with HCV and HIV testing. Chiron, in exchange for licensing HCV and HIV to Roche for diagnostic purposes, will receive up to $115 million from Roche, not counting future royalties. But their disagreement over rights to HCV and HIV for blood screening has yet to be resolved.
Advertisement

Related Content

Blood Brothers: Chiron and Gen-Probe
Blood Brothers: Chiron and Gen-Probe
Safe Blood At Any Cost?
Roche Diagnostics' New Marker Mandate

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel